Ipramol is a combination medication commonly used in the management and treatment of chronic obstructive pulmonary disease (COPD) and asthma. It combines two active ingredients: ipratropium bromide, which is an anticholinergic that works by relaxing the muscles around the airways so that they open up, and salbutamol (also known as albuterol in some regions), which is a short-acting β2-adrenergic receptor agonist that helps to alleviate symptoms by also relaxing the muscles in the airways and increasing air flow to the lungs. Ipramol is typically administered through inhalation, allowing the medication to act directly in the lungs for rapid effect. This dual-action approach helps to improve breathing, control symptoms, and prevent the frequency of asthma attacks or exacerbations of COPD, making it an essential treatment option for individuals with these respiratory conditions.